Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Evie Koslosky
Period: Reporting periods mapped to calendar 2026 Q1 – 2026 Q2 (2 quarters).
- Questions
- 7on tracked calls
- Challenge rate
- 0%none of 7 questionsLimited sample
- Companies
- 2questioned at least once
- Reporting periods
- 2with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 7 of 7 questions from 2 companies
WATWaters Corporation4 questions · 2 reporting periods · 0 of 4 challenging
Calendar 2026 Q2
How much of this is incremental versus just kind of shifting geographies?
Show response
Batra framed reshoring as incremental in the short-to-medium term (2027-2030) with ~70% of tracked sites being Waters accounts, but declined to quantify the tailwind yet.
how much of the guidance raise in the acquired business is related to pricing?
Show response
Chaubal quantified net price realization at 0.9% in Q2 vs the traditional 0.5%, raising the assumption to 0.9% for the rest of the year toward the 150bps goal.
Calendar 2026 Q1
can you talk to the decision to localize the manufacturing in flow cytometry in China
Show response
Udit framed China localization as replicating the Analytical Sciences playbook. Noted pharma in China grew 50%+ and roughly 1/3 of all biotech molecules licensed by large pharma now come from China. Manufacturing starts Q3 at Suzhou site.
can you talk to the mid-teens growth in chemistry
Show response
Udit credited R&D investment in bioseparations and new product stream. Upgraded mid-to-long-term chemistry growth from 7% to 9%-10%. Amol guided 6.5% for full year, noting Q2 had some pull forward and strong prior year comps.
MTDMettler Toledo3 questions · 2 reporting periods · 0 of 3 challenging
Calendar 2026 Q2
Are you starting to see pharma invest more heavily in sort of lab in the loop and automation capabilities
Show response
Patrick cited innovation and automation broadly across the lab portfolio, with Shawn adding that increased certainty is helping biopharma spend.
Calendar 2026 Q1
what sort of demand are you seeing for your bioreactor sensors as people look to drive automation in their facilities?
Show response
Patrick said MTD competes strongly in bioprocessing with new digital sensors and sees no slowdown amid GLP-1 build-outs.
Can you remind us what your exposure there is as a percentage of revenue
Show response
Patrick sized semiconductor exposure as low single-digit of revenue, growing well including data center cooling demand.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| WAT Waters Corporation | 4 | 0%none of 4 questions |
| MTD Mettler Toledo | 3 | 0%none of 3 questions |
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2026 Q1 | 4 | 0%none of 4 questions | 2 |
| 2026 Q2 | 3 | 0%none of 3 questions | 2 |
- 2026 Q14 questions · challenge rate 0% (none of 4 questions) · 2 companies
- 2026 Q23 questions · challenge rate 0% (none of 3 questions) · 2 companies
Topics
Topics tagged on this analyst’s questions.
- Demand3
- Innovation & R&D2
- Geographic Expansion2
- Revenue Growth2
- Capex Investment1
- Pricing1
- M&A1
- Competitive Dynamics1
- Product Launch1